We are live on ! Find out more
BCLSI

Bain Capital Life Sciences Investors Portfolio holdings

AUM $1.11B
1-Year Est. Return 171.34%
This Fund
S&P 500
This Quarter Est. Return
-28.93%
1 Year Est. Return
+171.34%
3 Year Est. Return
+643.23%
5 Year Est. Return
+451.99%
10 Year Est. Return
–
AUM
$293M
AUM Growth
-$148M
Cap. Flow
+$5.39M
Cap. Flow %
1.84%
Top 10 Hldgs %
100%
Holding
6
New
–
Increased
1
Reduced
–
Closed
–

Top Buys

Rank Stock Value
1
MRNS
Marinus Pharmaceuticals, Inc
MRNS
+$5.39M

Top Sells

No sells this quarter

Sector Composition

Rank Sector Weight
1 Healthcare 62.43%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
DRNA
1
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
$95.5M 32.62%
8,930,237
– –
IFRX icon
2
InflaRx
IFRX
$271M
$64.2M 21.93%
1,764,888
– –
SLDB icon
3
Solid Biosciences
SLDB
$900M
$53.3M 18.22%
132,630
– –
APTX
4
DELISTED
Aptinyx Inc. Common Stock
APTX
$36.8M 12.58%
2,225,092
– –
REPL icon
5
Replimune Group
REPL
$1.01B
$28.4M 9.7%
2,838,968
– –
MRNS
6
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
$14.5M 4.95%
1,260,684
+266,321
+27% +$5.39M

Similar funds

SL
Sentinus LLC Oak Brook, Illinois $1.11B AUM 17.13% 1-Year Est. Return
JTWM
Jackson Thornton Wealth Management Montgomery, Alabama $1.11B AUM 22.53% 1-Year Est. Return
RWM
RKL Wealth Management Lancaster, Pennsylvania $1.11B AUM 18.99% 1-Year Est. Return
EIA
Emerald Investment Advisers Leola, Pennsylvania $1.11B AUM
HH
Hilltop Holdings Dallas, Texas $1.11B AUM 24.7% 1-Year Est. Return
RIM
Rockbridge Investment Management Syracuse, New York $1.11B AUM 13.62% 1-Year Est. Return
YL
YCG LLC Austin, Texas $1.1B AUM 4.87% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

Bain Capital Life Sciences Investors's Q4 2018 Portfolio in Review

As of Q4 2018, Bain Capital Life Sciences Investors held 6 positions worth $293M, down 34% from $441M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Trading was light in Q4 2018: portfolio turnover was 0%. Bain Capital Life Sciences Investors opened no new positions and made no exits, leaving the 6-position portfolio largely intact.

By sector, the portfolio is most concentrated in Healthcare at 62% of assets, up from 60% a quarter earlier.

  • Bain Capital Life Sciences Investors added most to Marinus Pharmaceuticals, Inc in Q4 2018, an estimated $5.39M increase.
  • Bain Capital Life Sciences Investors's ten largest holdings make up 100% of its $293M portfolio in Q4 2018.
  • Bain Capital Life Sciences Investors opened 0 new positions and closed 0 in Q4 2018.
  • Bain Capital Life Sciences Investors's portfolio value fell 34% quarter-over-quarter to $293M.

Based on Bain Capital Life Sciences Investors's 13F filing for Q4 2018, filed 14 Feb 2019.